Neuromuscular rate of force development deficit in Parkinson disease.
This note indexes a cited or audit-added source. It may be an original study, review, guideline, form or methods reference. Treat the specific design and the evidence below as authoritative; a source note is not automatically a primary study.
DOI: 10.1016/j.clinbiomech.2017.04.003
Bibliographic record from the original reports
Access labels embedded in these original reference strings are historical. Current access and exact checked components are stated separately below.
Hammond KG, Pfeiffer RF, LeDoux MS, Schilling BK. Neuromuscular rate of force development deficit in Parkinson disease. Clin Biomech (Bristol). 2017;45:14–18. DOI 10.1016/j.clinbiomech.2017.04.003
Conditions: COND-PD Parkinson’s disease
Scoped audit evidence
These are source- and component-level audit summaries as of 3 October 2026. Access and comparison scope can differ by report; none certifies every result or the underlying raw data.
Parkinson’s disease — strength
- access status: full_main_text_available
STR-36-04
STR-36-01
STR-36-02
STR-36-03
Limitations: Only current scoped checks; archived captures not authenticated against live originals.
Parkinson’s disease strength
- current access: full_main_text_available
- primary version: Archived licensed publisher HTML/text capture; figure captions only
Parkinson’s disease strength component — Full quadriceps RFD and stimulation protocol and missing parameters
Methods 1.2 gives a right ankle cuff and load cell, knee at 90°, printed hip position “100° extension, ” upright supported chair, trunk/lap straps and arms crossed. Practice MVCs preceded two MVC trials, superimposed triplets at the force plateau and evoked octets for involuntary RFD. A fourth-order 30 Hz Butterworth filter preceded maximum differentiation; onset was the last derivative zero crossing. Sampling rate and stimulus repetition frequency are absent. The report correctly preserves the ambiguous hip-angle wording.
Source locator: https://doi.org/10.1016/j.clinbiomech.2017.04.003; Library original archived audit evidence Methods 1.2 and Figure 1 caption
Limitations: AI-assisted comparison with archived licensed capture; transcription accuracy was not independently verified against the live publisher original.
Parkinson’s disease strength component — Final sample, duration, outcomes and exclusion discrepancy
Table 1 declares seven PD participants and six controls, with sex counts 6/1 and 4/2, PD duration 7.9 years (SD 5.01), and HY 1.5 for one and HY 2 for six. Recruitment and exclusions instead imply eight PD participants and five controls, with sex counts 5/3 and 3/2; the total 17→13 is consistent. Abstract voluntary-RFD p=.008, d=1.97 and ratio p=.004, d=2.18 match. Other differences were nonsignificant. RFD means/dispersion appear graphically, with pixels unavailable in the capture, so effect sizes cannot be recomputed. No PD retest, MIC or longitudinal progression validation was conducted.
Source locator: https://doi.org/10.1016/j.clinbiomech.2017.04.003; Library original archived audit evidence Abstract, Methods1.1, Results, Table1, Figure2 caption
Limitations: RFD figure pixels/raw data unavailable; reported effect sizes remain source-reported rather than independently recomputed. AI-assisted comparison with archived licensed capture; transcription accuracy was not independently verified against the live publisher original.
Reports citing this source
- Strength muscle power and rapid force production assessment in Parkinson’s disease · reference 36 · original reference
Update record
- 2026-10-03: Created from the supplied reports and final scoped audit. New evidence should be appended with source version, access date, exact locator and affected report links.
Updating the wiki · Evidence and status guide